|Bid||92.95 x 800|
|Ask||92.99 x 800|
|Day's Range||91.70 - 95.64|
|52 Week Range||29.86 - 99.83|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The shares of CareDx (CDNA) rose 1.4% to $88.59 on June 8 after it acquired Transplant Hero, a New York-based app provider that focuses on helping transplant patients manage their medications. The financial terms of the deal have not been disclosed so far. CareDx is a molecular diagnostics company that is into the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The acquisition is expected to enhance CareDx’s dig
CareDx just posted 76% year-over-year revenue growth for the first quarter and raised its 2021 guidance.
CareDx (CDNA) delivered earnings and revenue surprises of 1500.00% and 10.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?